To the Editor: In his Editorial, Dr Wilt1 described the relative lack of reliable evidence
for treatment of prostate cancer, and then suggested the need for well-conducted
randomized controlled trials (RCTs) to lessen the uncertainty that surrounds
many treatments for prostate cancer. However, it will only be through systematic
reviews of all relevant randomized trials that patients and health care professionals
will be provided with a reliable summary of the evidence.2
Without such reviews, there is a danger that those involved in the treatment
of prostate cancer will simply switch from selective citing of opinion to
selective citing of randomized trials. Systematic reviews, such as those from
the Cochrane Collaboration, should underpin the design of every randomized
trial and are vital to the interpretation of the results of every trial. Unfortunately,
this seems to be the exception and it needs to become the rule.3
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 7
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.